Loading
A phase 1/2 trial of YL202, Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07169994 by MediLink Therapeutics (Suzhou) Co., Ltd., with 414 participants planned, started 2025-09-02 and due to reach its primary completion in 2026-09-01. Interventions recorded: YL202 for injection; Toripalimab injection, YL202 for injection; Furmonertinib Mesilate Tablets. Conditions listed: Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
Shares YL202, MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
Shares YL202, MediLink Therapeutics.
Shares YL202, MediLink Therapeutics.
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Toripalimab, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/